BNTCHIGH SIGNALFINANCIAL10-K

BNTC is restating prior financial statements due to material errors in share-based compensation accounting caused by incorrect system configuration during a November 2023 data migration.

The company's acknowledgment that previously filed financial statements cannot be relied upon for multiple periods represents a significant internal control failure and accounting breakdown. While the errors are described as non-cash in nature, the need for a comprehensive restatement rather than amended filings suggests management and auditor concerns about the reliability of historical financial reporting, which could impact investor confidence and regulatory scrutiny.

Comparing 2025-09-22 vs 2024-09-26View on EDGAR →
FINANCIAL ANALYSIS

The financial statements show dramatic deterioration in operating performance with net losses increasing 649% to $37.9M and R&D expenses surging 411% to $18.3M, though this appears largely driven by the restatement adjustments for previously understated share-based compensation. Paradoxically, the balance sheet strengthened significantly with cash nearly doubling to $97.7M and stockholders' equity more than doubling to $97.3M, while liabilities declined substantially, suggesting the company completed a major financing round during the period that more than offset the restated losses.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-649.5%
-$5.1M-$37.9M

Net income declined 649.5% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-621.2%
-$5.8M-$41.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
+411.4%
$3.6M$18.3M

R&D investment increased 411.4% — signals commitment to future product development, though near-term margin impact.

Stockholders Equity
Balance Sheet
+105.9%
$47.2M$97.3M

Equity base grew 105.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+92.2%
$50.9M$97.7M

Cash position surged 92.2% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+90.8%
$52.2M$99.6M

Asset base grew 90.8% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+90.7%
$51.7M$98.5M

Current assets grew 90.7% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-89.9%
$179K$18K

Capex reduced 89.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
-63.4%
$4.9M$1.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-53.7%
$5.0M$2.3M

Liabilities reduced 53.7% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2025-09-22
PRIOR — 2024-09-26
ADDED
s (the Company ) Annual Report on Form 10-K for the fiscal year ended June 30, 2025, the Company determined that in prior periods it had not appropriately recorded certain non-cash share-based compensation expenses.
As previously announced in the Current Report on Form 8-K filed with the U.S.
As a result of these misstatements, the Company is restating financial information for the Non-Reliance Periods.
All restated financial information for the Non-Reliance Periods is included in this Annual Report on Form 10-K and the Company has not filed, and does not intend to file, amendments to any of its filings that it has previously filed with the SEC.
Restatement Background The errors and corrective adjustments identified by the Company are non-cash in nature and resulted from the migration, in November 2023, of equity awards data to a new information recording system used to calculate the Company s share-based compensation expense, which was incorrectly configured resulting in understatements of share-based compensation expense, which in turn led to understatements of additional paid-in capital, accumulated deficit, net loss and loss per share.
+7 more — sign up free →
REMOVED
There were 10,555,728 shares of the Registrant s common stock, $0.0001 par value per share, outstanding on September 1 7 , 2024.
Certain Relationships and Related Transactions, and Director Independence III-2 Item 14.
On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited.
The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life- threatening genetic disorder.
Our Strengths We believe that the combination of our proprietary ddRNAi and silence and replace technology, and our deep expertise in the design and development of genetic medicines, will enable us to achieve and maintain a leading position in gene silencing and gene therapy for the treatment of human disease.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →